Description
Product Usage Information
Western Blotting: 1:1000
Immunoprecipitation: 1:200
Flow Cytometry (Fixed/Permeabilized): 1:300 - 1:1200
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting, Immunoprecipitation, Flow Cytometry (Fixed/Permeabilized)
Specificity / Sensitivity
Phospho-IFNAR2 (Tyr512) (F6M9J) Rabbit Monoclonal Antibody recognizes endogenous levels of IFNAR2 protein only when phosphorylated at Tyr512.
Species Reactivity: Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr512 of human IFNAR2 protein.
Background
Interferon alpha/beta receptor 2 (IFNAR2) is one of the two protein subunits that comprise the type I interferon (IFN-I) surface receptor. IFNAR2 is a class II helical cytokine receptor with an ectodomain composed of two fibronectin type III-like subdomains, D1 and D2, and an unstructured intracellular domain (ICD) (1,2). IFNAR2 is expressed on most nucleated cells (3). IFN-Is bind the IFN receptor, leading to the dimerization of IFNAR2 and IFNAR1 subunits, and the activation of Janus family kinase (JAK) and signal transducer and activator of transcription (STAT) signaling pathways (4,5). JAK1 is associated with IFNAR2, and STAT1 and STAT2 are constitutively bound to the intracellular domain (ICD) of IFNAR2 (6,7). The formation of the transcription factor IFN-stimulated gene factor 3 (ISGF3), which is a complex made up of the pSTAT1-pSTAT2 heterodimer and interferon regulatory factor 9 (IRF-9), leads to the transcription of interferon-stimulated genes (ISGs) (8). IFN-I subtypes have differential binding affinity toward IFNAR2, contributing to differences in response potency (9). In contrast, IFN-αs all bind IFNAR1 with a low affinity and only IFN-β binds IFNAR1 with a relatively higher affinity (10). IFN-I signaling mediates various cellular responses, including antiviral responses, immunomodulatory responses, and antiproliferative effects (3). In the tumor microenvironment (TME), the presence of IFN-I signaling is associated with "hot" tumors in which key effector immune cells are present and is predictive of therapeutic response, whereas suppressed IFN-I signaling in the TME is associated with tumor progression and poorer outcomes (11,12). IFN-I signaling is being investigated as a therapeutic target for cancer, autoimmunity, sepsis, and viral infection (13,14). In humans, the IFNAR2 ICD has seven tyrosine residues (269, 306, 316, 318, 337, 411, and 512), and mouse IFNAR2 has six (268, 315, 317, 335, 398, and 510) (15). The phosphorylation of these tyrosines enhances downstream signaling, likely by causing dissociation of activated STATs from IFNAR2 (16).
Alternate Names
human interferon alpha/beta receptor; IFN-alpha binding protein; IFN-alpha-REC; IFN-alpha/beta receptor 2; IFN-R; IFN-R-2; IFNABR; IFNAR2; IFNARB; IMD45; INAR2; interferon (alpha, beta and omega) receptor 2; interferon alpha and beta receptor subunit 2; Interferon alpha binding protein; Interferon alpha/beta receptor 2; interferon receptor; interferon-alpha/beta receptor beta chain; Type I interferon receptor 2
